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We assessed the applicability of multi-strain bacterial bioreporter bioassays to drug screening. To this
end, we investigated the reactions of a panel of 15 luminescent recombinant Escherichia coli bacterial
bioreporters to a library of 420 pharmaceuticals. The panel included bacterial bioreporters associated
with oxidative stress, DNA damage, heat shock, and efﬂux of excess metals. Eighty nine drugs elicited a
response from at least one of the panel members and formed distinctive clusters, some of which con-
tained closely related drugs. In addition, we tested a group of selected nine drugs against a collection of
about 2000 different ﬂuorescent transcriptional reporters that covers the great majority of gene pro-
moters in E. coli. The sets of induced genes were in accord with the in vitro toxicity of the tested drugs, as
reﬂected by the response patterns of the 15-member panel, and provided more insights into their
toxicity mechanisms. Facilitated by microplates and robotic systems, all assays were conducted in high-
throughput. Our results thus suggest that multi-strain assemblages of bacterial bioreporters have the
potential for playing a signiﬁcant role in drug development alongside current in vitro toxicity tests.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the main challenges in the drug discovery and development
process practiced by the pharmaceutical industry is determining the
activity and safety proﬁles of drug candidates. To this end, a wide
range of in vitro, in vivo, and in silico methods is applied (Eddershaw
et al., 2000; Gleeson et al., 2011). Included in this battery of tools are
whole-cell bioassays, some of which use genetically engineered bac-
teria, often referred to as bacterial bioreporters.
Bacterial bioreporters are based on the promoter–reporter concept,
according to which a host cell is transformed with an expression
vector that carries a transcriptional fusion of a gene promoter to a DNA
sequence encoding one of several possible reporter systems.When the
gene promoter is activated, the resulting construct synthesizes the
reporter protein(s), producing a readily quantiﬁable dose-dependent
signal. Their non-invasively measurable output, as well as their fast
response and easy handling, render bacterial bioreporters appealing
for effect analysis (de las Heras et al., 2010; Gu et al., 2004; van der
Meer and Belkin, 2010).
The most represented among bacterial bioreporter assays in
drug discovery and development are the umu (Oda et al., 1985)B.V. This is an open access article uand Vitotox tests (vanderLelie et al., 1997). Placing colorimetric
and bioluminescent reporter genes under the control of DNA da-
mage-inducible gene promoters, these tests allow drug developers
to effectively assess the genotoxicity of newly synthesized com-
pounds in a high-throughput manner (Reifferscheid and Hell,
1996; Verschaeve et al., 1999; Yu and Adedoyin, 2003).
The incorporation of genotoxicity bacterial bioreporters in lead
identiﬁcation and optimization has been accompanied by the de-
velopment of additional bacterial bioreporters. By fusing the ap-
propriate stress-responsive gene promoters upstream to reporting
gene systems, the present authors and others have constructed
bacterial strains designed to report on cellular stresses other than
DNA damage, including protein misfolding, fatty acid synthesis
inhibition, an increased production of reactive oxygen species, and
an excessive presence of metals (Ahn et al., 2010; Belkin et al.,
1997; Ben-Israel et al., 1998; Hynninen et al., 2010; Ivask et al.,
2009; Vandyk et al., 1994). Moreover, advances in robotics have
prompted the assembly of comprehensive bacterial bioreporter
collections that cover a substantial fraction of the gene promoters
in a given test bacterium. Such collections make it possible to draw
informative gene expression maps by reagent-less, non-destruc-
tive, real-time, easy-to-execute procedures (Elad and Belkin, 2013;
Elad et al., 2010; Melamed et al., 2012; Van Dyk et al., 2001; Za-
slaver et al., 2006).
We project that the utilization of the broader spectrum of
possibilities offered by bacterial bioreporters can provide morender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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chemicals and thus improve decision making in drug discovery. In
an attempt to critically examine this projection, this article de-
scribes the reactions of a panel of 15 luminescent bacterial bior-
eporters to a library of 420 FDA-approved drugs, as well as those of
a genome-wide collection of 2000 ﬂuorescent transcriptional
reporters to 9 drugs.2. Materials and methods
2.1. Drug library screening assay
A comprehensive library of 420 drugs approved by the United
States Food and Drug Administration (Selleckchem, Houston, TX)
was used (see Supplementary Table S1 for a complete list of 420
drugs). The drug library was screened against a selected panel of
15 luminescent recombinant Escherichia coli reporter strains, each
harboring a plasmid carrying a fusion of the Photorhabdus lumi-
nescens luxCDABE gene cassette to a stress-speciﬁc gene promoter
as well as an ampicillin resistance marker (Supplementary Tables
S2 and S3). The bacterial reporter strains are hereafter designated
by the lux-fused gene promoter they carry. Each reporter strain
was separately challenged with each drug as follows: a fresh col-
ony was used to inoculate LB broth (2 ml; 10 g/L tryptone, 5 g/L
yeast extract, 5 g/L NaCl) supplemented with ampicillin
(100 μg/mL; Sigma, St. Louis, MO) in a glass tube. The cells were
grown overnight at 37 °C with shaking (200 rpm). The overnight
culture was diluted 100-fold in fresh LB broth (100 ml) and re-
grown under the same conditions till the mid-logarithmic growth
phase (OD600 nm E0.3). Aliquots (20 μL) of the bacterial sus-
pension were then distributed across 420 wells of white 384-well
microtiter plates with a transparent bottom (Greiner Bio-One
GmbH, Frickenhausen, Germany), each of which preloaded with a
different drug from the library dissolved in 4% DMSO at a con-
centration of 400 μM (20 μL; ﬁnal drug concentration was
200 μM). Negative controls without addition of drugs and positive
controls containing a speciﬁc model inducer for each reporter
strain were also included. Luminescence and absorbance (630 nm)
were measured at 15–20 min intervals for 6 h by use of a micro-
titer plate reader (Synergy HT; BioTek, Winoosky, VT).
2.2. Promoter fusion library assay
A comprehensive library of ﬂuorescent transcriptional reporters
(Elad and Belkin, 2013; Zaslaver et al., 2006) was used. The library
consists of plasmid-borne transcriptional fusions of gfp to each of
∼2000 different E. coli K12 gene promoters, covering the great
majority of gene promoters in this bacterium. The reporter strains
were maintained in a 25% glycerol solution at 80 °C in 384-well
microplates. The stock reporter strain library was pin-replicated
into black 384-well microtiter plates with a transparent bottom
(Greiner Bio-One GmbH, Frickenhausen, Germany) containing
culture medium (10 g/L tryptone, 5 g/L NaCl, 2 g/L glucose, 11.9 g/L
HEPES; 20 μL/well). The plates were incubated for 3 h at 37 °C with
200 rpm shaking and then augmented with distilled water spiked
with a challenge drug or with distilled water only as control (20 μL/
well). Finally, the plates were incubated at 37 °C for ca. 7 h, during
which ﬂuorescence (485 nm excitation/535 nm emission) and ab-
sorbance (630 nm) were measured at 35 min intervals by use of a
microplate reader (Synergy HT; BioTek, Winoosky, VT). For both the
drug library assay and the promoter fusion library assay liquid and
plate handling was facilitated by a robotic system (MICROLABs
STAR; Hamilton Robotics, Inc., Reno, NV).2.3. Data analysis
For the drug library assay, the slopes of the linear trend lines of
the curves representing the difference between the luminescence
levels of the induced samples and the untreated controls were
calculated using linear regression. The slopes were standardized
by strain, and drugs that affected at least one strain to a level of at
least one standard deviation above the mean were considered as
eliciting a response. The response-eliciting drugs were hier-
archically clustered using correlation distance and average linkage.
For the promoter fusion library assay, identiﬁcation of activated
gene promoters was based on the curves representing the ratio
between the ﬂuorescence levels of the exposed and unexposed
reporter cells. Speciﬁcally, each gene promoter was given a score
equal to the sum of the differences between consecutive time
points on the curve described above. A high score indicated an
increase of the sample to control ratio over time and thus potential
promoter activation. The curves representing the difference be-
tween the ﬂuorescence levels of the induced samples and the
untreated controls were less effective in this case, owing to a bias
in favor of gene promoters with a high basal expression level. The
top ranked gene promoters from each drug challenge experiment
were analyzed for gene ontology (GO) term enrichment by use of
DAVID Bioinformatics Resources 6.7 (Huang et al., 2009a, 2009b);
p-Values reported are EASE scores adjusted for multiple compar-
isons by Benjamini–Hochberg correction (Benjamini and Hoch-
berg, 1995). The top ranked gene promoters from each drug
challenge experiment were also pooled. For each drug, a gene
promoter was marked with “1” if it was activated or with a “0” if it
was not. The drugs were then hierarchically clustered using
Hamming distance and average linkage. In both the drug library
assay and the promoter fusion library assay, hierarchical clustering
was performed by use of MeV software (Saeed et al., 2003).3. Results
A comprehensive library of 420 FDA-approved drugs was tested
against a panel of 15 luminescent reporter bacteria strains previously
demonstrated to respond to diverse cellular stress conditions (Sup-
plementary Tables S2 and S3). Out of the tested drugs, 89 elicited a
positive response (at least one standard deviation above the mean)
from at least one of the panel members (Fig. 1). Of these, 60 activated
oxidative stress reporters, 40 activated DNA damage reporters, 8 acti-
vated a heat shock reporter, and 2 induced the expression of a metal
efﬂux system, with some overlap (Fig. 2). In addition, and based on
their in vitro toxicity as reﬂected by the responses of the reporter
bacteria panel, the 89 tested positive drugs formed distinctive clusters,
many of which contained closely related drugs (Fig. 1). A few of the
more distinctive compound clusters were: (a) drugs that activated
DNA damage reporters encompassing triﬂuridine, stavudine and di-
danosine, all nucleoside analogs active against viral infections (Fig. 1,
Cluster A); (b) drugs that activated the oxidative stress reporters sodA
and soxS, encompassing mercaptopurine and thioguanine, purine
antimetabolites used as immunosuppressants (Fig. 1, Cluster C);
(c) drugs that activated DNA damage reporters (excluding nrdA) and
protein misfolding reporter grpE, encompassing ﬂuoroquinolone an-
tibiotics (Fig. 1, Cluster D); (d) drugs that activated DNA damage re-
porters, encompassing the alkylating agents methazolastone and da-
carbazine used in cancer treatment, anthracyclines doxorubicin and
epirubicin, which intercalate DNA strands and are also used against
cancer, glimepiride, an antidiabetic drug, ﬂuvastatin, a HMG-CoA re-
ductase inhibitor used to treat hypercholesterolemia and to prevent
cardiovascular disease, and olanzapine, an antipsychotic for the
treatment of schizophrenia and bipolar disorder (Fig. 1, Cluster G);
(e) drugs that activated metal reporter zntA, encompassing chloroxine,
Fig. 1. A heat map displaying the response-eliciting drugs (rows) and the induced
bacterial reporters (columns). The color bar represents the standardized expression
level, calculated as described under Section 2. Drugs and reporters were hier-
archically clustered using correlation distance and average linkage. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
Fig. 2. A Venn diagram describing how many drugs elicited each stress and
overlaps.
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used to treat chronic alcoholism (Fig. 1, Cluster H); (f) drugs that ac-
tivated reporter yqjF and oxidative stress reporter katG, encompassing
carbidopa and benserazide, Parkinson's disease drugs which inhibits
the conversion of L-DOPA (INN levodopa) to dopamine by DOPA dec-
arboxylase, as well as levodopa and dopamine themselves (Fig. 1,
Clusters I and J). Other examples of closely related drugs that clustered
together were dapoxetine and ﬂuoxetine, antidepressants of the se-
lective serotonin reuptake inhibitor (SSRI) family, and biapenem and
doripenem, broad spectrum carbapenem antibiotics (Fig. 1, Cluster F).
Several examples of the kinetics of bioluminescence development
following reporter activation are depicted in Fig. 3.
Following the drug library screen, nine selected drugs, namely
disulﬁram, chloroxine, stavudine, didanosine, gatiﬂoxacin, nor-
ﬂoxacin, thioguanine, mercaptopurine, and ﬂuvastatin were tested
against a comprehensive library of ﬂuorescent transcriptional re-
porters (Zaslaver et al., 2006). The library consisted of plasmid-
borne transcriptional fusions of gfp to each of ∼2000 different E.
coli gene promoters, covering the great majority of gene promoters
in this bacterium. Table 1 lists the nine drugs, the gene ontology
terms enriched by each, and the corresponding genes the pro-
moters of which were activated. The set of genes induced by sta-
vudine, gatiﬂoxacin, and norﬂoxacin was enriched with genes in-
volved in the SOS global response to DNA damage, including sulA,
polB, lexA, recA, and uvrA (p Values of 2.0103, 2.2106, and
2.5105, respectively). Similarly, the set of genes upregulated by
ﬂuvastatin was enriched with genes involved in base excision re-
pair (p Value¼4.8104). Gatiﬂoxacin and norﬂoxacin also in-
duced the transcription of a statistically signiﬁcant proportion of
ribosomal protein genes (p Values of 7.1107 and 1.0109,
respectively). Enrichment in iron and metal transport genes
characterized the responses to both disulﬁram and chloroxine (p
Valueso5.0105). These included bfd, encoding a bacter-
ioferritin-associated ferredoxin, cirA, encoding a siderophore re-
ceptor; fes, encoding an enterochelin esterase; fecI, encoding a
minor sigma factor that initiates transcription of ferric citrate
transport genes; zntA, encoding an ATPase involved in the efﬂux of
lead, cadmium and zinc; and yohL, regulating the expression of an
efﬂux protein that maintains nickel and cobalt homeostasis (Iwig
and Chivers, 2009; McHugh et al., 2003). No gene ontology en-
richment was detected for didanosine, thioguanine, and mercap-
topurine (Table 1). On an individual level, however, didanosine
induced the expression of SOS response genes polB and recA, and
the purine analogs immunosuppressants thioguanine and mer-
captopurine both caused a distinguishably high expression of
Fig. 3. Representative examples of the bioluminescent responses of bacterial reporters to selected drugs. Response of: (a) recA to triﬂuridine (antiviral); (b) soxS to bor-
tezomib (anticancer); (c) grpE to lomeﬂoxacin (antibiotic); (d) sulA to ﬂuvastatin (anti-cholesterol); (e) sulA glimepiride (antidiabetic); (f) sulA to olanzapine (antipsychotic);
(g) zntA to disulﬁram (treats chronic alcoholism); (h) yqjF to naftopidil (antihypertensive); and (i) katG to azelastine (antihistamine). Luminescence was measured in relative
light units (RLU) and was divided by the optical density at wavelength 630 nm (OD630) to correct for variations in cell density. Full and empty circles represent the treated
sample and the untreated control, respectively.
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perfamily (MFS) involved in the carbon control network (Fried
et al., 2013).
The most highly activated gene promoters from each of the
nine screening experiments were collected and the tested drugs
were clustered based on this information. The nine marketed
pharmaceuticals formed distinctive clusters in agreement with
their class attributions and the abovementioned results. Speciﬁ-
cally, the pairs stavudine/didanosine and gatiﬂoxacin/norﬂoxacin
pairs clustered together, forming a distinctive cluster along with
ﬂuvastatin, with disulﬁram/chloroxine and thioguanine/mercap-
topurine clustering separately (Fig. 4).4. Discussion
The last two decades have witnessed an extensive development
of bacterial bioreporter bioassays. Bacterial bioreporters sharemany of the basic metabolic properties of mammalian tester cells,
while being simpler to grow, maintain, and manipulate. Thus, in
many cases, bacterial bioreporters can serve as effective indicators
of higher organism toxicity, as demonstrated by genotoxicity as-
says such as the umu test (Judson et al., 2013; Reifferscheid and
Hell, 1996).
Put together to form multi-strain assemblages, bacterial bior-
eporters have been successfully used to detect and characterize a
broad range of environmental hazards (Belkin et al., 1997; Elad
et al., 2011; Elad and Belkin, 2013; Gou et al., 2014; Kessler et al.,
2012; Kim and Gu, 2005; Min et al., 2003; Su et al., 2014). Here we
examined the applicability of multi-strain bacterial bioreporter
assemblages to drug screening. Our results show, for what is to our
best knowledge the ﬁrst time, that bacteria also respond to a wide
span of pharmaceuticals not a priori intended to exert an effect on
prokaryotic cells, and that their response, as mediated by report-
ing systems, can indicate the substances’ nature regardless of their
mode of action as drugs.
Table 1
Gene ontology (GO) enrichment analysis.
Drug Enriched GO
term
Genes p Valuea
Disulﬁram Iron ion
transport
bfd, cirA, fes, fhuA, fecI 2.5106
Metal ion
transport
bfd, cirA, fes, fhuA, fecI, zntA,
yohL
4.9105
Chloroxine Iron ion
transport
bfd, cirA, fes, fecI, tonB 3.5108
Metal ion
transport
bfd, cirA, fes, fecI, tonB, zntA 2.4106
Stavudine SOS response sulA, polB, ftsK, lexA, dinG,
recA, uvrA
2.0103
Didanosine NDb – –
Gatiﬂoxacin Ribosome rpsJ, rpsO, rpsU, rpmB 7.1107
SOS response sulA, polB, dinB, recN, lexA,
recA, umuD, ssb, ybfE, uvrA
2.2106
Norﬂoxacin Ribosome rpsJ, rpsO, rpsU, rpsT, rpmB 1.0109
SOS response sulA, polB, dinB, recN, ftsK,
lexA, recA, umuD, ssb, uvrA
2.5105
Thioguanine ND – –
Mercaptopurine ND – –
Fluvastatin Base excision
repair
mutY, ligA, polA 4.8104
a p Values were adjusted for multiple comparisons.
b Not detected; no enrichment in signiﬁcant GO terms was detected.
Fig. 4. A dendrogram for nine selected drugs tested against a genome-wide E. coli
promoter-reporter fusion library. The drugs were hierarchically clustered on the
basis of the pool of the most responsive gene promoters from all challenge ex-
periments, as described under Section 2. Similar drugs grouped together, sug-
gesting that they exerted a similar effect on the test bacterium on the genome level.
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ﬂux as well as a statistically signiﬁcant portion of iron transport
genes (Figs. 1 and 3, and Table 1). Disulﬁram inhibits aldehyde de-
hydrogenase (ALDH) via a number of possible mechanisms, causing
high sensitivity to alcohol consumption. In addition to its primary
action as an ALDH inhibitor, disulﬁram is also known to complex
metals (Cvek and Dvorak, 2007). Disulﬁram's interaction with me-
tals may disrupt cellular iron homeostasis, as signaled by the bac-
terial bioreporters. The ﬂuoroquinolone antibiotics gatiﬂoxacin and
norﬂoxacin acted as expected from drugs in their class, inducing
SOS response genes in both the drug library screening assay and the
promoter fusion library assay. These two compounds have ad-
ditionally induced heat shock response, as indicated by the grpE
reporter. Indeed the genome-wide analysis, which showed upre-
gulation of ribosomal protein genes, supported this observation, as
ribosomal protein genes were previously reported to be upregulated
by exposure to ethanol, a known inducer of heat shock genes,
including grpE (Elad and Belkin, 2013; Vandyk et al., 1994). The
ribosomal protein gene products may chaperone protein folding, as
has recently been hypothesized (Kovacs et al., 2009).In some cases, the bacterial bioreporters’ indication challenged
existing ﬁndings, as manifested in the activation of DNA damage
reporters by ﬂuvastatin, a cholesterol-lowering agent (Figs. 1 and
3). Further examination of the bacterial bioreporters' response
patterns reveals that ﬂuvastatin induced oxidative stress (Fig. 1)
and base excision repair (Table 1); the latter has an important role
in preventing mutations associated with oxidative damage to DNA
(David et al., 2007). Based on these results it may be postulated
that ﬂuvastatin inﬂicts upon the tester cells ROS-mediated DNA
damage repaired in part by base excision. In contrast, no evidence
of ﬂuvastatin genotoxicity was observed in vitro or in vivo in
studies that utilized a variety of microbial or rodent cells (Robison
et al., 1994). Similarly, glimepiride, an antidiabetic drug, was found
here to have a genotoxic potential, while testing negative in a
battery of mutagenicity assays (Staff, 2008). More recently evi-
dence for glimepiride genotoxicity was provided in support of the
results of the drug library screen (Gurbuzel et al., 2014; Shaik et al.,
2010). Anti-HIV nucleoside analog reverse transcriptase inhibitors
(NRTIs) stavudine and didanosine produced negative results in the
Ames Salmonella mutagenicity assay. Stavudine was also not
mutagenic in the E. coli reversion assay. Both NRTIs, however, were
positive when tested against mammalian or human cells for, e.g.,
clastogenicity or chromosomal aberration, and have been the
subjects of ongoing genetic toxicity research (Guimaraes et al.,
2010). Their activation herein of DNA damage gene promoters thus
demonstrates that the bacterial bioreporters used in this study
may allow for the detection of compounds of carcinogenic concern
that were not detected by other bacteria-based tests.
The nine drugs tested against the promoter fusion library were
representatives of drug clusters formed in the drug library screen.
These nine compounds induced a total of 12 bioluminescent bac-
terial bioreporters in the drug library screen, 8 of which had
ﬂuorescent parallels in the promoter fusion library. The responses
of 4 of these 8 bioluminescent bioreporters, namely zntA, recA,
recN, and sulA, compared well with those of the ﬂuorescent
bioreporters of the same promoters. The responses of the other
4 bioluminescent bioreporters, grpE, sodA, soxS, and sbmC, were
not similarly matched by the members of the ﬂuorescent promoter
fusion library parallel to them. This discrepancy may be due to
differences in the promoter-containing segment fused upstream to
the reporting element (Yagur-Kroll et al., 2010). Overall, the results
of the drug library screen were indicative of those of the genome-
wide analysis.
In some cases, bioluminescence declined after reaching a peak
(Fig. 3A, C, H, and I). This phenomenon can be attributed in part to
an accumulating negative effect of the tested compound on cel-
lular wellbeing. Such an effect can also be manifested in a constant
decline of the signal, e.g. as for bacterial bioreporter DS1 in re-
sponse to dapoxetine and related drugs (Fig. 1, Cluster F). This
difference in signal behavior may stem from the identity of the
promoter to which the reporting system is fused. If the promoter is
activated in response to the stress inﬂicted upon the cell, the signal
may increase in intensity and then decline; otherwise a constant
decline of the signal may be observed. Another possible cause for
the decline in the light signal following a peak is lack of sufﬁcient
oxygen for the bioluminescence reaction to proceed.
Two approaches were introduced, which may either stand
alone or serve in tandem. The ﬁrst approach suggests using a se-
lected panel of stress-responsive bacterial bioreporters for high-
throughput toxicity screening in the early stages of drug discovery,
similarly and complementary to umu and other tests. Such efforts
help developers to ﬁlter out toxic compounds from a large number
of chemicals produced by combinatorial chemistry, and by this to
save valuable ﬁnancial and time resources that otherwise would
have been invested in drug candidates that would have eventually
failed regulatory tests. The second approach advocates the usage
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action, cellular pathway, and off-target effect analysis further
down the pipeline of drug discovery.
Procedures for putting the two approaches into practice were
laid out and demonstrated. Integrating microplate-based methods
with robotics, ca. 400 pharmaceuticals were screened against a
dozen different bacterial bioreporters in one week's time. The
process can be enhanced by arraying pharmaceuticals in 384-well
microplates (instead of 96-well microplates), which will allow
performing the same screen in one day. This throughput is com-
petitive with that of methods implemented today and meets the
criteria required of in vitro toxicity testing in the discovery phase
of drug development (Judson et al., 2013; Yu and Adedoyin, 2003).
By identical means, screening one drug against a comprehensive
promoter fusion library as described here was completed in a few
hours. Of additional value is the demonstration that bacterial
bioreporters may respond in a similar manner to drugs from the
same class, and may thus be used to predict the toxicity of a group
of pharmaceuticals that share similar targets.
An estimate of the false positive and false negative rates should
be calculated if we want to know this screening system is really
functional. However, since the purpose of the present study was
mostly aimed of proving the overall concept of using a bacterial
reporter library for drug screening, such calculations were re-
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